Compounds > 3'-azido-2',3'-dideoxyguanosine
Page last updated: 2024-10-15

3'-azido-2',3'-dideoxyguanosine

Cross-References

ID SourceID
PubMed CID135433653
CHEMBL ID578448
SCHEMBL ID15643042
MeSH IDM0145526

Synonyms (17)

Synonym
guanosine, 3'-azido-2',3'-dideoxy-
3'-azido-ddg
2-amino-9-[(2r,4s,5s)-4-azido-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1h-purin-6-one
azddguo
3'-azido-2',3'-dideoxyguanosine
66323-46-4
3'-n3ddg
CHEMBL578448
rfs-457
2-amino-9-[(2s,5r)-4-azido-5-(hydroxymethyl)tetrahydrofuran-2-yl]purin-6-ol
3'-azido-2'-3'-dideoxyguanosine
SCHEMBL15643042
2-amino-9-((2r,4s,5s)-4-azido-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1h-purin-6(9h)-one
3'-azido-2'-deoxyguanosine
2-amino-9-[(2r,4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-1h-purin-6-one
2-amino-9-((2r,4s,5s)-4-azido-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,9-dihydro-6h-purin-6-one
A855657
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (53)

Assay IDTitleYearJournalArticle
AID572993Mitochondrial toxicity in human HepG2 cells assessed as percent mitochondrial DNA production at 10 uM after 14 days by real-time PCR relative to control2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID452271Cytotoxicity against human CEM cells after 5 days2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Synthesis and evaluation of 3'-azido-2',3'-dideoxypurine nucleosides as inhibitors of human immunodeficiency virus.
AID436401Cytotoxicity against human PBMC cells2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
Synthesis, antiviral activity, and stability of nucleoside analogs containing tricyclic bases.
AID572986Cytotoxicity against human PBMC at < 50 to 100 uM after 2 to 4 days by MTT assay2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID572775Antiviral activity against HIV1 harboring reverse transcriptase L74V mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID572780Ratio of IC50 for HIV1 harboring reverse transcriptase M184V mutant infected in human HeLa P4/R5 cells to wild type HIV1 infected in human HeLa P4/R5 cells2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID572784Antiviral activity against HIV1 harboring reverse transcriptase D67N/K70R/T215F/K219Q mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID452269Antiviral activity against HIV1 LAI infected in human PBM cells after 5 days2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Synthesis and evaluation of 3'-azido-2',3'-dideoxypurine nucleosides as inhibitors of human immunodeficiency virus.
AID572982Cytotoxicity against human MT2 cells after 2 to 4 days by MTT assay2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID572981Cytotoxicity against human PBMC after 2 to 4 days by MTT assay2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID515880Antimalarial activity against Plasmodium falciparum 3D7 after 48 hrs by SYBR green assay2010Bioorganic & medicinal chemistry, Oct-15, Volume: 18, Issue:20
Potential application of thymidylate kinase in nucleoside analogue activation in Plasmodium falciparum.
AID572998Mitochondrial toxicity in human HepG2 cells assessed as percent inhibition of beta-actin DNA at 100 uM after 14 days by real-time PCR2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID572987Cytotoxicity against human MT2 cells at < 50 to 100 uM after 2 to 4 days by MTT assay2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID572785Antiviral activity against HIV1 harboring reverse transcriptase M41L/D67N/K70R/L210W/T215Y/K219Q mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID572972Antiviral activity against HIV1 harboring reverse transcriptase diserine insert between residues 69 and 70 infected in human HeLa P4/R5 cells assessed as inhibition of viral replication2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID572782Antiviral activity against HIV1 harboring reverse transcriptase M41L/L210W/T215Y mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID572776Antiviral activity against HIV1 harboring reverse transcriptase M184V mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID572974Ratio of IC50 for HIV1 harboring reverse transcriptase M41L/D67N/K70R/T215F/K219Q mutant infected in human HeLa P4/R5 cells to wild type HIV1 infected in human HeLa P4/R5 cells2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID572976Ratio of IC50 for HIV1 harboring reverse transcriptase M41L/D67N/K70R/L210W/T215Y/K219Q mutant infected in human HeLa P4/R5 cells to wild type HIV1 infected in human HeLa P4/R5 cells2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID572990Cytotoxicity against human HeLa P4/R5 cells at < 50 to 100 uM after 2 to 4 hrs by MTT assay2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID436403Cytotoxicity against african green monkey Vero cells2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
Synthesis, antiviral activity, and stability of nucleoside analogs containing tricyclic bases.
AID572992Mitochondrial toxicity in human HepG2 cells assessed as percent inhibition of mitochondrial DNA at 100 uM after 14 days by real-time PCR2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID572781Ratio of IC50 for HIV1 harboring reverse transcriptase Q151M mutant infected in human HeLa P4/R5 cells to wild type HIV1 infected in human HeLa P4/R5 cells2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID572973Ratio of IC50 for HIV1 harboring reverse transcriptase M41L/L210W/T215Y mutant infected in human HeLa P4/R5 cells to wild type HIV1 infected in human HeLa P4/R5 cells2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID572777Antiviral activity against HIV1 harboring reverse transcriptase Q151M mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID572774Antiviral activity against HIV1 harboring reverse transcriptase K65R mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID572779Ratio of IC50 for HIV1 harboring reverse transcriptase L74V mutant infected in human HeLa P4/R5 cells to wild type HIV1 infected in human HeLa P4/R5 cells2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID515879Antimalarial activity against Plasmodium falciparum 3D7 at 100 uM by SYBR green assay2010Bioorganic & medicinal chemistry, Oct-15, Volume: 18, Issue:20
Potential application of thymidylate kinase in nucleoside analogue activation in Plasmodium falciparum.
AID572783Antiviral activity against HIV1 harboring reverse transcriptase M41L/D67N/K70R/T215F/K219Q mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID572768Antiviral activity against HIV1 infected in human MT2 cells assessed as inhibition of viral replication2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID572994Mitochondrial toxicity in human HepG2 cells assessed as percent mitochondrial DNA production at 100 uM after 14 days by real-time PCR relative to control2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID572767Antiviral activity against HIV1 infected in human HeLa P4/R5 cells assessed as inhibition of viral replication2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID452270Cytotoxicity against human PBMC after 5 days2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Synthesis and evaluation of 3'-azido-2',3'-dideoxypurine nucleosides as inhibitors of human immunodeficiency virus.
AID572778Ratio of IC50 for HIV1 harboring reverse transcriptase K65R mutant infected in human HeLa P4/R5 cells to wild type HIV1 infected in human HeLa P4/R5 cells2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID452272Cytotoxicity against african green monkey Vero cells after 5 days2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Synthesis and evaluation of 3'-azido-2',3'-dideoxypurine nucleosides as inhibitors of human immunodeficiency virus.
AID572995Mitochondrial toxicity in human HepG2 cells assessed as percent lactic acid production at 10 uM after 14 days by real-time PCR relative to beta-actin DNA2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID436399Antiviral activity against HIV in human PBM cells by RNA replicon assay2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
Synthesis, antiviral activity, and stability of nucleoside analogs containing tricyclic bases.
AID572999Antiviral activity against HIV1 LAI infected in human MT2 cells assessed as inhibition of viral replication selected after 65 passages relative to wild type HIV1 LAI2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID572991Mitochondrial toxicity in human HepG2 cells assessed as percent inhibition of mitochondrial DNA at 10 uM after 14 days by real-time PCR2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID436400Antiviral activity against HCV in human Huh7 cells by RNA replicon assay2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
Synthesis, antiviral activity, and stability of nucleoside analogs containing tricyclic bases.
AID572996Mitochondrial toxicity in human HepG2 cells assessed as percent lactic acid production at 100 uM after 14 days by real-time PCR relative to beta-actin DNA2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID572769Antiviral activity against HIV1 infected in human PBMC assessed as inhibition of viral replication2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID572988Cytotoxicity against african green monkey Vero cells at < 50 to 100 uM after 2 to 4 days by MTT assay2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID572997Mitochondrial toxicity in human HepG2 cells assessed as percent inhibition of beta-actin DNA at 10 uM after 14 days by real-time PCR2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID572978Cellular uptake in PHA-stimulated human PBMC assessed as accumulation of 3'-Azido-ddGTP after 12 hrs by LC-MS analysis2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID572977Ratio of IC50 for HIV1 harboring reverse transcriptase diserine insert between residues 69 and 70 infected in human HeLa P4/R5 cells to wild type HIV1 infected in human HeLa P4/R5 cells2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID572983Cytotoxicity against african green monkey Vero cells after 2 to 4 days by MTT assay2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID572985Cytotoxicity against human HeLa P4/R5 cells after 2 to 4 hrs by MTT assay2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID572979Drug level in PHA-stimulated human PBMC measured per 10'6 cells at 10 uM after 12 hrs by LC-MS analysis2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID572984Cytotoxicity against human CEM cells after 2 to 4 days by MTT assay2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID572975Ratio of IC50 for HIV1 harboring reverse transcriptase D67N/K70R/T215F/K219Q mutant infected in human HeLa P4/R5 cells to wild type HIV1 infected in human HeLa P4/R5 cells2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID436402Cytotoxicity against human CEM cells2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
Synthesis, antiviral activity, and stability of nucleoside analogs containing tricyclic bases.
AID572989Cytotoxicity against human CEM cells at < 50 to 100 uM after 2 to 4 days by MTT assay2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (11.76)18.7374
1990's2 (11.76)18.2507
2000's8 (47.06)29.6817
2010's5 (29.41)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
purine
1H-purine : The 1H-tautomer of purine.. 3H-purine : The 3H-tautomer of purine.. 9H-purine : The 9H-tautomer of purine.. 7H-purine : The 7H-tautomer of purine.		1.9810purine
hydroxyurea
[no description available]		1.9710one-carbon compound;
ureas		antimetabolite;
antimitotic;
antineoplastic agent;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
genotoxin;
immunomodulator;
radical scavenger;
teratogenic agent
thymidine
[no description available]		1.9810pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite
cytarabine
[no description available]		2.0210beta-D-arabinoside;
monosaccharide derivative;
pyrimidine nucleoside		antimetabolite;
antineoplastic agent;
antiviral agent;
immunosuppressive agent
2'-deoxyadenosine triphosphate
2'-deoxyadenosine triphosphate: RN given refers to unlabeled parent cpd		2.05102'-deoxyadenosine 5'-phosphate;
purine 2'-deoxyribonucleoside 5'-triphosphate		Escherichia coli metabolite;
mouse metabolite
stavudine
Stavudine: A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.. stavudine : A nucleoside analogue obtained by formal dehydration across positions 2 and 3 of thymidine. An inhibitor of HIV-1 reverse transcriptase		2.0510dihydrofuran;
nucleoside analogue;
organic molecular entity		antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
dideoxyadenosine
Dideoxyadenosine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is an inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal side effect is nephrotoxicity. In vivo, dideoxyadenosine is rapidly metabolized to DIDANOSINE (ddI) by enzymatic deamination; ddI is then converted to dideoxyinosine monophosphate and ultimately to dideoxyadenosine triphosphate, the putative active metabolite.		2.4520adenosines;
purine 2',3'-dideoxyribonucleoside		EC 3.5.4.4 (adenosine deaminase) inhibitor;
EC 4.6.1.1 (adenylate cyclase) inhibitor
zalcitabine
Zalcitabine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.. zalcitabine : A pyrimidine 2',3'-dideoxyribonucleoside compound having cytosine as the nucleobase.		2.4620pyrimidine 2',3'-dideoxyribonucleosideantimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
azides
Azides: Organic or inorganic compounds that contain the -N3 group.. azide : Any nitrogen molecular entity containing the group -N3.		2.0610pseudohalide anionmitochondrial respiratory-chain inhibitor
zidovudine
Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.		3.2960azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
3'-azido-2',3'-dideoxyuridine
[no description available]		2.0510
lamivudine
[no description available]		2.0510monothioacetal;
nucleoside analogue;
oxacycle;
primary alcohol		allergen;
anti-HBV agent;
antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor;
HIV-1 reverse transcriptase inhibitor;
prodrug
emtricitabine
Emtricitabine: A deoxycytidine analog and REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B viruses. It is used to treat HIV INFECTIONS.. emtricitabine : An organofluorine compound that is 5-fluorocytosine substituted at the 1 position by a 2-(hydroxymethyl)-1,3-oxathiolan-5-yl group (2R,5S configuration). It is used in combination therapy for the treatment of HIV-1 infection.		2.0510monothioacetal;
nucleoside analogue;
organofluorine compound;
pyrimidone		antiviral drug;
HIV-1 reverse transcriptase inhibitor
adenosine
quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit		7.0710adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent
thymidine 5'-triphosphate
thymidine 5'-triphosphate: RN given refers to parent cpd. dTTP : A thymidine phosphate having a triphosphate group at the 5'-position.		2.0510pyrimidine 2'-deoxyribonucleoside 5'-triphosphate;
thymidine phosphate		Escherichia coli metabolite;
mouse metabolite
2'-deoxycytidine 5'-triphosphate
2'-deoxycytidine 5'-triphosphate: RN given refers to unlabeled parent cpd		2.05102'-deoxycytidine phosphate;
pyrimidine 2'-deoxyribonucleoside 5'-triphosphate		Escherichia coli metabolite;
human metabolite;
mouse metabolite
2',3'-didehydro-2',3'-dideoxyuridine
[no description available]		2.0510
2',3'-dideoxyadenosine triphosphate
[no description available]		2.0510purine deoxyribonucleoside triphosphate
stavudine triphosphate
stavudine triphosphate: shows termination substrate properties in DNA synthesis catalyzed by several different DNA polymerases; also abbreviated d4TTP		2.0510
3'-azido-2,6-diaminopurine-2',3'-dideoxyriboside
3'-azido-2,6-diaminopurine-2',3'-dideoxyriboside: structure given in first source		2.4520
zidovudine triphosphate
[no description available]		2.0510
2',3'-dideoxycytidine 5'-triphosphate
2',3'-dideoxycytidine 5'-triphosphate: inhibits vesicular stomatitis virus RNA synthesis		2.0510
3'-azido-2',3'-dideoxyadenosine
[no description available]		2.7530
3'-azido-2',3'-dideoxycytidine
[no description available]		2.0610
lamivudine triphosphate
[no description available]		2.0510
tenofovir diphosphate
[no description available]		2.0510
tenofovir disoproxil fumarate
tenofovir disoproxil fumarate : A fumarate salt prepared from equimolar amounts of tenofovir disoproxil and fumaric acid. It is used in combination therapy for the treatment of HIV infection.		2.0510fumarate saltantiviral drug;
HIV-1 reverse transcriptase inhibitor;
prodrug
deoxyguanosine
[no description available]		7.3720purine 2'-deoxyribonucleoside;
purines 2'-deoxy-D-ribonucleoside		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
deoxyguanosine triphosphate
[no description available]		2.0510deoxyguanosine phosphate;
guanyl deoxyribonucleotide;
purine 2'-deoxyribonucleoside 5'-triphosphate		Arabidopsis thaliana metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
guanosine
ribonucleoside : Any nucleoside where the sugar component is D-ribose.		1.9810guanosines;
purines D-ribonucleoside		fundamental metabolite
didanosine
Didanosine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite.. didanosine : A purine 2',3'-dideoxyribonucleoside that is inosine in which the hydroxy groups at both the 2' and the 3' positions on the sugar moiety have been replaced by hydrogen. An antiviral drug, it is used as a medication to treat HIV/AIDS.		2.0510purine 2',3'-dideoxyribonucleosideantimetabolite;
antiviral drug;
EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor;
geroprotector;
HIV-1 reverse transcriptase inhibitor
2-aminopurine dioxolane
(4-2-aminopurin-9-yl)-1,3-dioxolane-2-methanol: structure in first source		2.0510
nsc 614846
carbovir: structure given in first source; potent & selective anti-HIV agent. carbovir : Cyclopent-2-en-1-ylmethanol in which the 4-position is substituted by a 2-amino-6-hydroxy-9H-purin-9-yl group such that the two substitutents on the cyclopentene ring are in a cis relationship. The (-)-enantiomer, also known as carbovir, is a potent inhibitor of HIV replication replication in cell cultures.. (-)-carbovir : The (active) (-)-enantiomer of the carbocyclic analogue of 2',3'-dideoxy-2',3'-didehydroguanosine.		2.0510carbovirHIV-1 reverse transcriptase inhibitor
triacetylguanosine
[no description available]		1.9810
carbovir triphosphate
carbovir triphosphate: metabolite of abacavir. carbovir triphosphate : The organic triphosphate that is the 5'-triphosphate of (-)-carbovir.		2.0510organic triphosphate
ConditionIndicatedRelationship StrengthStudiesTrials
HIV
Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.		02.420
HIV Coinfection
[description not available]		02.0510
HIV Infections
Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).		02.0510
Acute Lymphoid Leukemia
[description not available]		01.9710
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.		01.9710
Cell Transformation, Viral
An inheritable change in cells manifested by changes in cell division and growth and alterations in cell surface properties. It is induced by infection with a transforming virus.		01.9710